Moderna News & Analysis
3 articles
Market Mood
10% of Cystic Fibrosis Patients Still Await Effective Treatment
Approximately 10% of cystic fibrosis patients do not benefit from recent advancements in CF treatments, which use drugs like Trikafta. These drugs, made by Vertex Pharmaceuticals, enhance the CFTR protein function for 90% of patients, transforming the disease into a more manageable condition. However, the remaining 10% of patients, born with other genetic mutations, experience a lack of effective treatment. Recent scientific efforts, including attempts by Vertex and Moderna using mRNA technology and Boehringer Ingelheim's gene therapy trials, were halted due to tolerability issues and other challenges. Emily's Entourage, a nonprofit founded by Emily Kramer-Golinkoff, has played a key role in continuing research for these patients. Since its inception in 2011, it has raised over $22 million, funding 51 research projects that explore novel treatments like antisense oligonucleotides and small molecules. Delivering drugs to affected lung cells poses significant scientific challenges because of the lungs' natural defenses and the presence of thick mucus in CF patients. This matters to ordinary investors as ongoing research might open opportunities for pharmaceutical companies to address the unmet needs of these patients, potentially leading to breakthroughs that could impact company valuations and future investment decisions.
Read More: 10% of Cystic Fibrosis Patients Still Await Effective Treatment
Apple (AAPL) and other Stocks Showing Notable Premarket Moves
In the premarket, several stocks including Apple (AAPL), Chevron, Amazon, and Moderna are experiencing notable moves. Replimune, Chevron, and other companies featured in the list could indicate changes in investor sentiment. Watching these stocks might reveal shifts that can impact market performance. This information is valuable for investors looking to make informed trading decisions based on premarket activity.
Read More: Apple (AAPL) and other Stocks Showing Notable Premarket Moves
Market Movers: Moderna Settles COVID Patent Dispute, Boosting Stock Value
Moderna's shares surged following the announcement of a $2.25 billion settlement related to a COVID vaccine patent dispute, which alleviated concerns about potential legal liabilities affecting its future. This settlement, which includes a $1 billion payment to settle litigation with Arbutus, removes a significant overhang from the company's stock, potentially restoring investor confidence. Meanwhile, Coinbase and other cryptocurrency stocks also experienced notable gains, contributing to an overall positive sentiment in the markets, as optimism around the crypto sector appears to be gaining traction. The combination of these developments may lead to increased trading volumes and heightened investor interest in both healthcare and cryptocurrency sectors.
Read More: Market Movers: Moderna Settles COVID Patent Dispute, Boosting Stock Value